Analytical Data
-
Gene name
Tet2
- Application
-
Alternative Names
Protein Ayu17-449 (Kiaa1546)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His-KSI
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q4JK59
-
Expression Region
1810-1912aa
-
Molecular Weight
27.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TET2 (Tet Methylcytosine Dioxygenase 2) is a member of the TET family of enzymes that play a critical role in the active demethylation of DNA, thereby influencing gene expression and cellular differentiation. Aberrant TET2 function has been implicated in various hematological malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Mutations and dysregulation of TET2 are frequently observed in these conditions, highlighting its importance in hematopoiesis and tumorigenesis. Research on TET2 recombinants has gained momentum as scientists aim to elucidate its biochemical mechanisms and interactions with other epigenetic regulators. The study of TET2 recombinant proteins provides insights into their structural and functional properties, which are critical for understanding how TET2-mediated DNA demethylation processes can influence cancer progression and treatment responses. Furthermore, advances in recombinant DNA technology allow for the generation of TET2 variants, enabling the exploration of specific mutation effects and the design of potential therapeutic approaches targeting this enzyme in malignancies. Ultimately, a deeper understanding of TET2 function through recombinant studies may pave the way for novel epigenetic therapies aimed at re-establishing normal gene expression patterns in cancer cells.
